A Study of Benralizumab in Patients With Eosinophilic Esophagitis
Public ClinicalTrials.gov record NCT04543409. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The aim of this Phase 3 study is to investigate the use of benralizumab as a treatment for patients with EoE. The effect of doses of benralizumab on EoE histologic signs and symptoms will be assessed over a 52-week treatment period (including a 24-week double-blind placebo-controlled treatment period and a 28-week open-label treatment period). It is proposed that benralizumab will deplete eosinophils from GI tissue(s), improve the symptoms of dysphagia, and improve endoscopy scores as well as other markers of disease activity. Upon completion of the initial 52-week treatment period, patients will be offered an additional Open Label Extension period of at least 1 year, with benralizumab treatment and ongoing study assessments.
Study identification
- NCT ID
- NCT04543409
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 211 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 22, 2020 (Actual)
- Primary completion
- Sep 19, 2022 (Actual)
- Completion
- Feb 6, 2023 (Actual)
- Last update posted
- Nov 18, 2023
2020 – 2023
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Little Rock | Arkansas | 72202 | — |
| Research Site | St. Petersburg | Florida | 33709 | — |
| Research Site | Atlanta | Georgia | 30322-1013 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Normal | Illinois | 61761 | — |
| Research Site | Park Ridge | Illinois | 60068 | — |
| Research Site | White Marsh | Maryland | 21162 | — |
| Research Site | Boston | Massachusetts | 02111 | — |
| Research Site | Boston | Massachusetts | 02115 | — |
| Research Site | Chesterfield | Michigan | 48047 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | Lincoln | Nebraska | 68510 | — |
| Research Site | Ocean City | New Jersey | 07712 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | Chapel Hill | North Carolina | 27514 | — |
| Research Site | Winston-Salem | North Carolina | 27157 | — |
| Research Site | Cincinnati | Ohio | 45229 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Uniontown | Pennsylvania | 15401 | — |
| Research Site | Salt Lake City | Utah | 84107 | — |
| Research Site | Salt Lake City | Utah | 84132 | — |
| Research Site | Richmond | Virginia | 23219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04543409, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2023 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04543409 live on ClinicalTrials.gov.